Stockreport

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF Following BYSANTI's approval, the firm's revenue model for Vanda has been updated, reflecting expected growth in the psychiatry franchise with peak BYSANTI sales now inc [Read more]